http://exhibits.library.stonybrook.edu/mfp/files/original/ea9cef0c902bde7e53a34d9e1027884f.pdf cbcd38a374f07061a269cf9a18d90526 PDF Text Text E g E E E August 3, 1970 i ”“5“ "-1-“. W ""‘fi'vmffldr'd’aJ'Fu-JKWu'yy‘n-w Dr. Jack Freund, Vice President A. H. Robins Company 1407 Cummings hrive Richmond, Virginia 23220 Dear Jack, I have read the reports on sulpiride (Dogmatil) with interest. data consists of translations from French of 17 clinical studies and one animal assay, published 1968-1969. The principal clinical reports of Borenstein gt_§&; (Ann. Med. Paychol., 1: 90~99, 1968; and 2; 560~74, 1968) are frequently cited but are lacking in this The collection. In the continental manner, case records are cited in general terms and it is difficult to assess the data. Four groups of patients have been treated: schizophrenia, depressive psychosis, depressive neurosis and neurovegitative disorders. I found the reports of Collard (1969), Mathey gt §£;.(19693 and Naviau (1969) best for clinical material, and that of Borenstein 33 a1. (1969) for an animal EEG study. From these data, it is probable that: l. sulpiride, 300-1600 mg/day, is an agent, with alerting and stimulating features; active antipsychotic 2. it may have less potential for parkinsonism or seizures than other active antipsychotic compounds; 3. it has antidepressant activity, particularly in agitated, elderly patients (Renault. 1969); and, 4. it has some anti-vertigo activity anxiolytic features in neurovegitative states. and may have other citations are difficult to interpret, since the reader is faith in the observers (it is assumed that they are known, or that their clinic will carry the weight of authority behind the observations), and controlled data are not presented. These asked to have �-"-~“"W«W"‘ "‘N‘”V~w- "W- \"n' s ' u . ~ . ‘YW‘WV1”'WWx-r4umw"‘fiwa-H'll'xw'va u.1~~r)'w'-UL-rwwmuw—-V". -.wo-u~.~u-‘_..,ru “—um-v-uwr WM!" n; ,1 < anvvnrurv- "yur'""b.'z my...“ -2- Dr. Freund August 3, 1970 I have known P. Borenstein since 1958. He is an able electroencephalographer and clinician. He is dour, carries a heavy burden of studies, publishes often and has well trained European assistants. In Liege, in Harch 1959, I heard him discuss a new, all-purpose psychoactive compound, with well defined EEG activity. I don't recall the name of the drug, for he told me that the compound was not available for American studies; but I believe it must have been sulpiride. His enthusiasm did not get a good reception, since many in the audience were preoccupied by other new compounds, chiefly pimozide and fluspiriline, two Janssen compounds in early clinical trial. (The conference was in Liege with Janssen support, and many of the participants were his investigators.) Collard’s report is also a good one. I know the director of his choice, Professor Bobon, as well as his son. They are enthusiastic and probably able psychoPharmacologists, and perhaps these observations should be treated seriously. . If you seek another psychoactive compound, the data of these studies are sufficiently supportive of a broad spectrum antipsychotic (and antidepressant?) to warrant further study. It also has interesting anti-vertigo properties to support its antipsychotic potency. I would suggest Borenstein's initial reports he read and his present views be obtained. Also, the present views of Collard and to visit these centers, to discuss the clinical material in detail, and to assess comparisons with other active compounds in the same clinics. In the case of Borenstein, it would be interesting to review his EEG material. Bobon and Naviau. It may be useful I am attending the CINP in Prague in midsAugust. As this is a biennial Opportunity to discuss new compounds, I have checked the list of titles and sulpiride appears only once. J. M. Sutter, g£_&l;, of Marseille are reading: effects of a new drug: ”Controlled study of the psychotropic Sulpiride.” for the opportunity to review this material. It that I should take better notes at huronean clinical meetings, and will try to do so. (I am returning the translation separately.) Thank you reminded My me best regards. Sincerely yours, Max Fink, M.D. Professor of Psychiatry MF:kt cc: Dr. Tabor � Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Correspondence Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Correspondence to: Freund, Jack Type The nature or genre of the resource Text Identifier An unambiguous reference to the resource within a given context mfp-05-00-024-8-456 Date A point or period of time associated with an event in the lifecycle of the resource 1970 Creator An entity primarily responsible for making the resource <a title="Fink, Max, 1923-" href="http://id.loc.gov/authorities/names/n79039548" target="_blank">Fink, Max, 1923-</a> Subject The topic of the resource Correspondence -- Correspondence Relation A related resource The Max Fink Collection Description An account of the resource Rights Information about rights held in and over the resource <a title="IN COPYRIGHT - EDUCATIONAL USE PERMITTED" href="http://rightsstatements.org/vocab/InC-EDU/1.0/" target="_blank">IN COPYRIGHT - EDUCATIONAL USE PERMITTED</a> Source A related resource from which the described resource is derived Special Collections and University Archives, University Libraries. Stony Brook University Libraries (State University of New York). Language A language of the resource en-US Format The file format, physical medium, or dimensions of the resource application/pdf Publisher An entity responsible for making the resource available Contributor An entity responsible for making contributions to the resource Correspondence